A protein that has long frustrated diabetes researchers is suddenly at the center of a very different fight. By targeting an enzyme called protein tyrosine phosphatase 1B, or PTP1B, scientists are ...

Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa ...

Scientists reveal how Candida auris survives on human skin by feeding on CO₂ and how blocking it could stop its spread.

Chronic pain affects more than 50 million Americans, yet for decades, treatment options for pain that persists in the absence of inflammation have been limited. Seventy-five percent of these patients, ...

A protein long implicated in diabetes and obesity may hold the key to treating Alzheimer’s disease by reinvigorating the brain’s immune system. New research suggests that blocking this protein, known ...

Colorectal cancer is one of the most prevalent tumors and a leading cause of cancer-related mortality. Despite advances achieved in recent years, resistance to available treatments remains one of the ...

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need ...

Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotypeBLA resubmitted to U.S. FDA in January 2026; ...

Xanthine oxidase inhibitors, primarily allopurinol and febuxostat, are the mainstay of treatment. The goal of chronic gout management includes lowering serum urate levels to below 6 mg/dL. 5 Overall, ...

September 17, 2008 (Munich, Germany) — A new study has found that early enzyme-replacement therapy brings the most benefit in patients with Fabry's disease. Dr Frank Weidemann (University Hospital ...

A clinical-stage biopharmaceutical company is testing a new targeted cancer treatment based on the notion that solid tumors can be compelled to develop their own chemotherapy and self-destruct. In PNP ...